Neon Therapeutics, Inc. NTGN Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Sep'17	Jun'17
Operating expenses:
Research and development
52,992	59,718	65,049	65,370	63,439	60,425	0	0	0	0	0
General and administrative
23,232	21,420	21,874	21,352	20,085	18,276	0	0	0	0	0
Total operating expenses
76,224	81,138	86,923	86,722	83,524	78,701	0	0	0	0	0
Loss from operations
-76,224	-81,138	-86,923	-86,722	-83,524	-78,701	0	0	0	0	0
Other income (expense), net
Interest income
913	1,401	1,907	2,301	2,101	1,792	0	0	0	0	0
Other expense
-	-	44	50	-	25	0	0	0	-	-
Total other income (expense), net
-	-	1,863	2,251	-	1,767	0	0	0	0	0
Net Income (Loss) Attributable to Parent
-75,350	-79,776	-85,060	-84,471	-81,438	-76,934	0	0	0	0	0
Temporary Equity, Accretion to Redemption Value, Adjustment
-	-	0	0	-	6,371	0	0	0	0	0
Net loss attributable to common stockholders
-	-	-85,060	-84,471	-	-83,305	0	0	0	0	0
Net loss per share, basic and diluted (in dollars per share)
-0.58	-0.63	-0.68	-0.79	-0.76	12.44	-0.67	-7.84	-9.47	-9.59	-7.55
Weighted average common shares outstanding, basic and diluted (in shares)
28,535	28,141	27,935	27,787	27,651	27,891	27,357	2,815	2,080	1,722	1,603
Comprehensive loss:
Net Income (Loss) Attributable to Parent
-75,350	-79,776	-85,060	-84,471	-81,438	-76,934	0	0	0	0	0
Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
8	75	24	2	0	-62	0	0	0	0	0
Total other comprehensive income
8	75	24	2	0	-62	0	0	0	0	0
Comprehensive loss
-75,342	-79,701	-85,036	-84,469	-81,438	-76,996	0	0	0	0	0